Effects of raloxifene on the renin-angiotensin-aldosterone system and blood pressure in hypertensive and normotensive osteoporotic postmenopausal women

Geriatrics and Gerontology International

Volumn 10, Issue 1, 2010, Pages 70-77

  Sumino, Hiroyuki ^a   Ichikawa, Shuichi ^b   Kasama, Shu ^b   Takahashi, Takashi ^c   Kumakura, Hisao ^b   Takayama, Yoshiaki ^b   Kanda, Tsugiyasu ^d   Murakami, Masami ^e   Kurabayashi, Masahiko ^f  

^a TAKASAKI UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^b Cardiovascular Hospital of Central Japan   (Japan)

^c Tokyo Metropolitan Health and Medical Treatment Corporation   (Japan)

^d KANAZAWA MEDICAL UNIVERSITY   (Japan)

^e Department of Clinical Laboratory Medicine ^*  (Japan)

^f GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Blood pressure; Postmenopausal women; Raloxifene; Renin angiotensin aldosterone system

Indexed keywords

ALDOSTERONE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; RALOXIFENE; RENIN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; HUMAN; HYPERTENSION; OSTEOPENIA; PATHOPHYSIOLOGY; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULSE RATE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYPERTENSION; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; RALOXIFENE; RENIN-ANGIOTENSIN SYSTEM; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 73049112752     PISSN: 14441586     EISSN: 14470594     Source Type: Journal    
DOI: 10.1111/j.1447-0594.2009.00562.x     Document Type: Article

References (41)

1. Paech K, Webb P, Kuiper GG. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 1997, 277:1508-1510.
2. Bryant HU, Glasebrook AL, Yang NN, Sato M. An estrogen receptor basis for raloxifene action in bone. J Steroid Biochem Mol Biol 1999, 69:37-44.
3. Cummings SR, Eckert S, Krueger KA. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from MORE randomized trial: Multiple Outcome of Raloxifene Evaluation. JAMA 1999, 281:2189-2197.
4. Barrett-Connor E, Grady D, Sashegyi A. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 2002, 287:847-857.
5. Barrett-Connor E, Mosca L, Collins P. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006, 355:125-137.
6. Burt VL, Whelton P, Roccella EJ. Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995, 25:305-313.
7. Steassen J, Bulpitt CJ, Fagard R, Lijnen P, Amery A. The influence of menopause on blood pressure. J Hum Hypertens 1989, 3:427-433.
8. van Beresteyn EC, vont Hof MA, De Waard H. Contributions of ovarian failure and aging to blood pressure in normotensive perimenopausal women: a mixed longitudinal study. Am J Epidemiol 1989, 129:947-955.
9. Ogihara T, Higashimori K, Masuo K, Mikami H. Pilot study of a new angiotensin II receptor antagonist, TCV-116: effects of a single oral dose on blood pressure in patients with essential hypertension. Clin Ther 1993, 15:684-691.
10. Kang PM, Landau AJ, Eberhardt RT, Frishman WH. Angiotensin II receptor antagonists: a new approach to blockade of the renin-angiotensin system. Am Heart J 1994, 127:1388-1401.
11. Ichikawa J, Sumino H, Ichikawa S, Ozaki M. Different effects of transdermal and oral hormone replacement therapy on the renin-angiotensin system, plasma bradykinin level, and blood pressure of normotensive postmenopausal women. Am J Hypertens 2006, 19:744-749.
12. Ichikawa A, Sumino H, Ogawa T, Ichikawa S, Nitta K. Effects of long-term transdermal hormone replacement therapy on the renin-angiotensin-aldosterone system, plasma bradykinin levels and blood pressure in normotensive postmenopausal women. Geriatr Gerontol Int 2008, 8:259-264.
13. Umeda M, Ichikawa S, Kanda T, Sumino H, Kobayashi I. Hormone replacement therapy increases plasma level of angiotensin II in postmenopausal hypertensive women. Am J Hypertens 2001, 14:206-211.
14. Sumino H, Ichikawa S, Ohyama Y. Effects of hormone replacement therapy on serum angiotensin-converting enzyme activity and plasma bradykinin in postmenopausal women according to angiotensin-converting enzyme-genotype. Hypertens Res 2003, 26:53-58.
15. Sumino H, Ichikawa S, Kanda T. Hormone replacement therapy in postmenopausal women with essential hypertension increases circulating plasma levels of bradykinin. Am J Hypertens 1999, 12:1044-1047.
16. Nogawa N, Sumino H, Ichikawa S. Effect of long-term hormone replacement therapy on angiotensin-converting enzyme activity and bradykinin in postmenopausal women with essential hypertension and normotensive postmenopausal women. Menopause 2001, 8:210-215.
17. Sumino H, Ichikawa S, Kumakura H. Effects of hormone replacement therapy on office and ambulatory blood pressure in Japanese hypertensive postmenopausal women. Hypertens Res 2003, 26:369-376.
18. Morgante G, Delia A, Musacchio MC, Severi FM, Petraglia F, de Leo V. Effects of raloxifene therapy on plasma rennin and aldosterone levels and blood pressure in postmenopausal women. Gynecol Endocr 2006, 22:376-380.
19. Kanis JA, Melton LJ, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res 1994, 9:1137-1141.
20. Chobanian AV, Bakris GL, Black HR. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003, 289:2560-2572. Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee
21. Hata Y, Mabuchi H, Saito Y. Report of the Japan Atherosclerosis Society (JAS) guideline for diagnosis and treatment of hyperlipidemia in Japanese adults. J Jpn Atheroscler Soc 2002, 9:1-27.
22. Yamamoto T, Hiromoto J, Kikuchi Y, Oka M, Takatori O. Correlations among blood levels of renib-angiotensin-aldosterone, bradykinin, and catecholamines in healthy subjects. Clin Chim Acta 1989, 181:197-200.
23. Kasahara Y, Ashihara Y. Colorimetry of angiotensin-I converting enzyme activity in serum. Clin Chem 1981, 27:1922-1925.
24. Gotoh M, Mizuno K, Ono Y, Takahashi M. High blood pressure, bone-mineral loss and insulin resistance in women. Hypertens Res 2005, 28:565-570.
25. Chetkowski RJ, Meldrum DR, Steingold KA. Biologic effects of transdermal estradiol. N Engl J Med 1986, 314:1615-1620.
26. Schunkert H, Danser AHJ, Hense HW, Derkx FHM, Kurzinger S, Riegger GAJ. Effects of estrogen replacement therapy on the rennin-angiotensin system in postmenopausal women. Circulation 1997, 95:39-45.
27. Hassager C, Riis BJ, Strom V, Guyene TT, Christiansen C. The long-term effect of oral and percutaneous estradiol on plasma rennin substrate and blood pressure. Circulation 1987, 76:753-758.
28. Seely EW, Walsh BW, Gerhard MD, Williams GH. Estradiol with or without progesterone and ambulatory blood pressure in postmenopausal women. Hypertension 1999, 33:1190-1194.
29. Faguer de Moustier B, Conard J, Guyene TT. Comparative metabolic study of percutaneous versus oral micronized 17β-oestradiol in replacement therapy. Maturitas 1989, 11:275-286.
30. Proudler AJ, Ahmed AIH, Crook D, Fogelman I, Rymer JM, Stevenson JC. Hormone replacement therapy and serum angiotensin-enzyme activity in postmenopausal women. Lancet 1995, 346:89-90.
31. Proudler AJ, Cooper A, Whitehead M, Stevenson JC. Effects of oestrogen-progestogen replacement therapy upon circulating angiotensin I-converting enzyme activity in postmenopausal women. Clin Endocr 2003, 58:30-35.
32. Cagnacci A, Zanni AL, Volpe A. Administration of raloxifene does not influence 24-hour ambulatory blood pressure of postmenopausal women with osteopenia: a double-blind placebo-controlled study. Am J Obstet Gynecol 2003, 188:1278-1282.
33. de Valk-de Roo GW, Stehouwer CD, Meijer P. Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: a 2-year, placebo-controlled study. Arterioscler Thromb Vasc Biol 1999, 19:2993-3000.
34. Figtree GA, Lu Y, Webb CM, Collins P. Raloxifene acutely relaxes rabbit coronary arteries in vitro by an estrogen receptor-dependent and nitric oxide-dependent mechanism. Circulation 1999, 100:1095-1101.
35. Zoma WD, Baker RS, Clark KE. Coronary and uterine vascular responses to raloxifene in the sheep. Am J Obstet Gynecol 2000, 182:521-528.
36. Wassmann S, Laufs U, Stamenkovic D. Raloxifene improves endothelial dysfunction in hypertension by reduced oxidative stress and enhanced nitric oxide production. Circulation 2002, 105:2083-2091.
37. Unger T. The role of the renin-angiotenisn system in the development of cardiovascular disease. Am J Cardiol 2002, 89:3A-9A.
38. Miura S, Saku K, Karnik SS. Molecular analysis of the structure and function of the angiotensin II type 1 receptor. Hypertens Res 2003, 26:937-943.
39. Staessen J, Lijnen P, Fagard R, Verschueren LJ, Amery A. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 1981, 91:457-465.
40. Lijnen P, Staessen J, Fagard R, Amery A. Increase in plasma aldosterone during prolonged captopril treatment. Am J Cardiol 1982, 49:1561-1563.
41. Ogihara T, Kikuchi K, Matsuoka H. The Japanese society of hypertension guidelines for the management of hypertension (JSH 2009). Hypertens Res 2009, 32:3-107.